Description: H&Q Life Sciences Investors is a close ended equity mutual fund launched and managed by Hambrecht & Quist Capital Management, LLC. The fund invests in the public equity markets across the globe. It invests in stocks of companies operating in the health technology and life sciences industries. It also invests in stocks of early and later stage financings of privately held companies, private placements by public companies. The fund invests in growth stocks of companies operating across all market capitalizations. It employs fundamental analysis with a focus on factors such as potential for above-average, long-term growth in revenues and earnings securities strong market position for their services or products, experienced business management, and, recognized technological expertise. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. H&Q Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Home Page: www.teklacap.com/hql.html
HQL Technical Analysis
100 Federal Street
Boston,
MA
02110
United States
Phone:
617 772 8500
Officers
| Name | Title |
|---|---|
| Dr. Daniel R. Omstead M.S, Ph.D. | Principal Exec. Officer, Pres and Trustee |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.961 |
| Price-to-Sales TTM: | 124.2319 |
| IPO Date: | 1992-05-04 |
| Fiscal Year End: | September |
| Full Time Employees: | 0 |